In the case of NCT04180046, primary GBM cell lines are going to be established from patient samples, in order to pathologically characterize the presence of GBM-related hallmarks (IDH1, GFAP, P53, ATRX and Ki67) and measure dose-response effects of natural and synthetic drugs [94]. This evidence concerns the gene IDH1 and glioblastoma.